First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Health Technology Assessment

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.3310/HTA7110PMID 12709291
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• First and Second Trimester Antenatal Screening for Down's Syndrome: The Results of the Serum, Urine and Ultrasound Screening Study (SURUSS)

  2003cited by this paper
• Absence of nasal bone and detection of trisomy 21.

  2002cited by this paper
• Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data

  2002cited by this paper
• A large‐scale evaluation of amnio‐PCR for the rapid prenatal diagnosis of fetal trisomy

  2001cited by this paper
• Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study.

  2001cited by this paper
• Development and implementation of a new rapid aneuploidy diagnostic service within the UK National Health Service and implications for the future of prenatal diagnosis.

  2001cited by this paper
• Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies.

  2001cited by this paper
• Prenatal diagnosis using fetal cells and free fetal DNA in maternal blood.

  2001cited by this paper
• Amniocentesis and chorionic villus sampling.

  2000cited by this paper
• Tests using multiple markers

  2000cited by this paper
• Fetal loss in Down syndrome pregnancies

  1999cited by this paper
• Antenatal Screening for Down's Syndrome

  1997cited by this paper
• Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.

  1996cited by this paper
• COMBINING INHIBIN A WITH EXISTING SECOND‐TRIMESTER MARKERS IN MATERNAL SERUM SCREENING FOR DOWN'S SYNDROME

  1996cited by this paper
• Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency thickness

  1996cited by this paper
• Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters.

  1995cited by this paper
• A new simple and rapid dual assay for AFP and free β hCG in screening for Down syndrome

  1994cited by this paper
• Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight

  1992cited by this paper
• Free Beta Human Choriogonadotropin in Down's Syndrome Screening: A Multicentre Study of its Role Compared with other Biochemical Markers

  1992cited by this paper
• Improved performance in a prenatal screening programme for Down's syndrome incorporating serum‐free hCG subunit analyses

  1992cited by this paper
• Dual Analyte Immunoassay—a New Approach to Neural Tube Defect and Down's Syndrome Screening

  1992cited by this paper
• Model-based screening by risk with application to Down's syndrome.

  1992cited by this paper
• Prenatal screening for chromosome abnormalities using maternal serum chorionic gonadotrophin, alpha‐fetoprotein, and age

  1991cited by this paper
• Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's syndrome.

  1991cited by this paper
• Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin.

  1990cited by this paper
• Maternal serum screening for Down's syndrome in early pregnancy.

  1988cited by this paper

• Generation and Exosomal Noncoding RNA Profiling of Down Syndrome-Specific Induced Pluripotent Stem Cells

  2026cites this paper
• Nuchal translucency in first trimester of pregnancy: a descriptive study

  2025cites this paper
• Antenatal diagnosis and counseling of birth defects: A modern renaissance in fetal care

  2025cites this paper
• Prenatal screening for trisomy 21 (Down syndrome) using first- and second-trimester biochemistry and nuchal translucency: A technical standard of the American College of Medical Genetics and Genomics (ACMG).

  2025cites this paper
• Ever-Evolving Importance of the 11 to 13+6 Weeks Fetal Ultrasonography

  2025cites this paper
• The Diagnostic Performance of Nuchal Translucency Alone as a Screening Test for Down Syndrome: A Systematic Review and Meta-analysis

  2025cites this paper
• Risk stratification in medical screening

  2024cites this paper
• Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation.

  2024cites this paper
• The association between hCG and adverse pregnancy outcomes: a systematic review and meta-analysis.

  2023cites this paper
• Screening for pre‐eclampsia with competing‐risks model using placental growth factor measurement in blood samples collected before 11 weeks' gestation

  2023cites this paper
• First and second trimester maternal serum markers for prenatal aneuploidy screening: an update on the adjustment factors for race, smoking, and insulin dependent diabetes mellitus.

  2023cites this paper
• Trisomy 21 screening with αlpha software and the Fetal Medicine Foundation algorithm.

  2023cites this paper
• Trisomy 21 Testing in Second Trimester: Reliability Comparison of Triple and Quadruple Testing in Pakistan

  2023cites this paper
• The Efficiency of First Trimester Screening Test: A Retrospective Study in a Referral Center in Turkey

  2023cites this paper
• Biochemical Serum Markers Influencing Maternal Age Risk for Down's Syndrome in Quadruple Marker

  2022cites this paper
• What are the predominant parameters for Down syndrome risk estimation in first-trimester screening: a data mining study

  2022cites this paper
• Health Supervision for Children and Adolescents With Down Syndrome.

  2022cites this paper
• Human Plasma Proteome During Normal Pregnancy.

  2022cites this paper
• Assessment of a Simplified Cell-Free DNA Method for Prenatal Down Syndrome Screening.

  2022cites this paper
• Screening for Chromosomal Anomalies

  2021cites this paper
• Down syndrome in women aged more than 35 Years positive detection rates

  2021cites this paper
• Performance of second-trimester maternal biochemistry screening (quadruple test vs. triple test) for trisomy 21: An Indian experience

  2021cites this paper
• Prenatal Diagnostic Testing Following High-Risk Result from Serological Screening: Which Shall We Select?

  2021cites this paper
• The effect of co-payments on the take-up of prenatal tests.

  2021cites this paper
• Genetic Screening of Cervical Cancer

  2021cites this paper
• Sonographic abnormalities in pregnancies conceived following IVF with and without preimplantation genetic testing for aneuploidy (PGT-A)

  2021cites this paper
• A machine learning model for the prediction of Down Syndrome in second trimester antenatal screening.

  2021cites this paper
• Prenatal serum screening for Down syndrome and neural tube defects in the United States: Changes in utilization patterns from 2012 to 2020

  2021cites this paper
• Chromosomal microarray analysis for pregnancies with abnormal maternal serum screening who undergo invasive prenatal testing

  2021cites this paper
• Optimising classification of Parkinson’s disease based on motor, olfactory, neuropsychiatric and sleep features

  2021cites this paper
• Prenatal Invasive Testing at a Tertiary Referral Center in India: A Report of 433 Cases Under a Single Operator

  2021cites this paper
• Performance of a universal prenatal screening program incorporating cell-free fetal DNA analysis in Ontario, Canada

  2021cites this paper
• Cost of providing cell-free DNA screening for Down syndrome in Finland using different strategies

  2021cites this paper
• A technical and clinical evaluation of the new ThermoFisher BRAHMS unconjugated estriol and inhibin-A assays and their use in second trimester Down syndrome screening

  2021influential citation
• Missed Down Syndrome Cases after First Trimester False-Negative Screening—Lessons to be Learned

  2020cites this paper
• Prenatal testing

  2020cites this paper
• Current landscape of prenatal genetic screening and testing

  2020cites this paper
• Maximising information on smell, quantitative motor impairment and probable REM-sleep behaviour disorder in the prediction of Parkinson’s disease

  2020cites this paper
• The predictive value of maternal serum screening tests for adverse pregnancy outcomes

  2020cites this paper
• Adjusting anti-Müllerian hormone levels for age and body mass index improves detection of polycystic ovary syndrome.

  2020cites this paper
• Mortality Among Children with Down syndrome in Hong Kong: A Population-Based Cohort Study from Birth.

  2020cites this paper
• Dental Implant Treatment in Medically Compromised Patients

  2020cites this paper
• Maternal Age and Pregnancy

  2020cites this paper
• Indigenization of the median of markers for Down syndrome screening based on statistical analysis of medical big data.

  2020cites this paper
• Estimation of median second trimester screening test values at a single hospital

  2020cites this paper
• A Toolkit for the Application of Placental-Fetal Molecular Biomarkers in Epidemiologic Studies of the Fetal Origins of Chronic Disease

  2020cites this paper
• A Cost-Effectiveness Analysis of Screening Strategies Involving Non-Invasive Prenatal Testing for Trisomy 21

  2020cites this paper
• First trimester prenatal screening in multiple pregnancies. Part I: comparative analysis of serum proteins PAPP-A and p-hCG in pregnancies conceived spontaneously or by in vitro fertilization

  2020cites this paper
• A comparison of first trimester prenatal screening strategies for Down Syndrome with maternal age and preferences considerations

  2020influential citation
• Ultrasound and Biochemical Screening for Fetal Aneuploidy

  2020cites this paper
• Optimizing Fetal Aneuploidy Screening in an Austere Military Clinical Environment: A Prenatal Cost Comparison.

  2020cites this paper
• Update in non-invasive prenatal testing.

  2019cites this paper
• The Contingent Prenatal Screening Test for Down’s Syndrome and Neural Tube Defects in West of Iran

  2019cites this paper
• Predicting Down syndrome and neural tube defects using basic risk factors

  2019cites this paper
• Cross-trimester marker ratios in prenatal screening for Down syndrome

  2019cites this paper
• Fetal Down syndrome screening models for developing countries; Part II: Cost-benefit analysis

  2019cites this paper
• Prenatal Genetic Testing Options.

  2019cites this paper
• Serum and Ultrasound Based Screening Tests for Aneuploidy

  2019cites this paper
• Normative Values of Second-Trimester Maternal Serum Markers Using an Automated Assay Platform for Down Syndrome Screening

  2019cites this paper
• Elecsys free βhCG

  2019cites this paper
• Other Conditions Affecting Dental Implant Treatment

  2019cites this paper
• FIRST TRIMESTER SCREENING FOR DOWN SYNDROME POLICY NUMBER : 2 . 02 . 25 CATEGORY : Laboratory Test EFFECTIVE

  2018cites this paper
• Prenatal screening for Down syndrome in twin pregnancies: Estimates of screening performance based on 61 affected and 7302 unaffected twin pregnancies

  2018cites this paper
• Cell-Free DNA-Based Non-invasive Prenatal Screening for Common Aneuploidies in a Canadian Province: A Cost-Effectiveness Analysis.

  2018cites this paper
• Trends in the use of prenatal testing services for fetal aneuploidy in Ontario: a descriptive study.

  2018cites this paper
• Association of CVS and Amniocentesis for Down Syndrome with Fetal Loss

  2018cites this paper
• Prenatal Biochemical and Ultrasound Markers in Chromosomal Anomalies

  2018cites this paper
• [What are the real purpose and scope of screening for aneuploidy?]

  2018cites this paper
• Chapter 5 Prenatal Diagnosis of Down Syndrome

  2018cites this paper
• Second‐trimester maternal serum screening for fetal Down syndrome: As a screening test for hemoglobin Bart's disease: A prospective population‐based study

  2018influential citation
• Repeated measures screening for down's syndrome

  2018influential citation
• Importance of the integrated test in the Down’s syndrome screening algorithm

  2018cites this paper
• First-trimester Combined Screening Test for Aneuploidies in Brazilian Unselected Pregnancies: Diagnostic Performance of Fetal Medicine Foundation Algorithm

  2018cites this paper
• Optimal risk cut-offs for Down syndrome contingent maternal serum screening

  2018cites this paper
• Prenatal screening and prenatal diagnosis with cordocentesis for prenatal chromosome abnormalities

  2018cites this paper
• The association between maternal serum first trimester free βhCG, second trimester intact hCG levels and foetal growth restriction and preeclampsia

  2018cites this paper
• Prenatal diagnosis

  2018cites this paper
• Down’s syndrome screening with hydrogel photonic barcodes

  2018cites this paper
• Evaluation of machine learning algorithms for improved risk assessment for Down's syndrome

  2018cites this paper
• Recommendation on laboratory screening of birth defects in the first and second trimesters of pregnancy. The first and second trimester screening system is based on an agreement between the laboratories, gynecologists and genetics

  2018cites this paper
• Enhanced First Trimester Aneuploidy Screening with Placental Growth Factor and Alpha Feto-Protein: Detection of Trisomies 18 and 13.

  2018cites this paper
• Prenatal Diagnosis of Down Syndrome

  2018cites this paper
• CRIBADO COMBINADO CON MARCADORES DE RESCATE ECOGRÁFICOS. SU UTILIDAD EN LA DISMINUCIÓN DE PROCEDIMIENTOS INVASIVOS DE DIAGNÓSTICO PRENATAL

  2017cites this paper
• Expanded conventional first trimester screening

  2017cites this paper
• Diagnosing Fetal Aneuploidy in Australia: The Impact of Prenatal Screening and the Integration of New Technology

  2017cites this paper
• Noninvasive prenatal testing for fetal aneuploidy and single gene disorders.

  2017cites this paper
• Screening for Fetal Abnormalities

  2017cites this paper
• Child-Parent Familial Hypercholesterolemia Screening in Primary Care.

  2017cites this paper
• Thai pregnant women knowledge and attitudes about maternal serum screening for Down’s syndrome

  2017cites this paper
• An Investigation of the Single and Combined Phthalate Metabolite Effects on Human Chorionic Gonadotropin Expression in Placental Cells

  2017cites this paper
• Combined screening test for trisomy 21 – is it as efficient as we believe?

  2017cites this paper
• First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

  2017cites this paper
• Observational study comparing the performance of first‐trimester screening protocols for detecting trisomy 21 in a North Indian population

  2017cites this paper
• Timing of delivery in a high-risk obstetric population: a clinical prediction model

  2017cites this paper
• Screening for fetal chromosomal and subchromosomal disorders.

  2017cites this paper
• Enhanced First Trimester Screening for Trisomy 21 with Contingent Cell-Free Fetal DNA: A Comparative Performance and Cost Analysis.

  2017cites this paper
• Age‐based differences in the predictive accuracy of a one‐size‐fits‐all risk‐cutoff value in prenatal integrated screening for Down syndrome

  2017cites this paper
• Title: Age-based Differences in the Predictive Accuracy of a One-Size-Fits-All Risk- Cutoff Value in Prenatal Integrated Screening for Down Syndrome Running Head: Age-based Differences in the Accuracy of Down Syndrome

  2017cites this paper
• Measuring maternal serum screening markers for Down’s syndrome in plasma collected for cell-free DNA testing

  2017cites this paper
• Economic analysis of prenatal screening strategies for Down syndrome in singleton pregnancies in Turkey.

  2017cites this paper